Schonfeld Strategic Advisors LLC Sells 60,610 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Schonfeld Strategic Advisors LLC trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 74.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,400 shares of the company's stock after selling 60,610 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Vaxcyte were worth $1,670,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after buying an additional 521,204 shares in the last quarter. Capital Research Global Investors grew its stake in Vaxcyte by 26.8% during the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after acquiring an additional 1,312,302 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Vaxcyte by 3.0% in the 4th quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock valued at $234,884,000 after purchasing an additional 82,997 shares during the period. Geode Capital Management LLC lifted its position in shares of Vaxcyte by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock worth $229,495,000 after purchasing an additional 102,106 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of Vaxcyte by 8.1% during the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock worth $145,659,000 after purchasing an additional 133,448 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total value of $670,800.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,180,820.35. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

PCVX has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research report on Tuesday, April 8th. Guggenheim reiterated a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Vaxcyte presently has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Price Performance

Shares of PCVX traded up $0.75 during mid-day trading on Monday, reaching $31.91. The company had a trading volume of 331,612 shares, compared to its average volume of 1,305,748. The company has a market capitalization of $4.12 billion, a P/E ratio of -6.93 and a beta of 1.27. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The company's 50-day moving average is $46.66 and its 200-day moving average is $74.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the business posted ($0.85) earnings per share. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.